NASDAQ: KURAKura Oncology Inc Stock
$6.52+0.01 (+0.15%)
Updated Apr 29, 2025
KURA Price
$6.52
Fair Value Price
$12.53
Market Cap
$526.52M
52 Week Low
$5.41
52 Week High
$23.48
P/E
-3.23x
P/B
1.27x
P/S
13.93x
PEG
N/A
Dividend Yield
N/A
Revenue
$53.88M
Earnings
-$173.98M
Gross Margin
100%
Operating Margin
-316.14%
Profit Margin
-322.9%
Debt to Equity
0.84
Operating Cash Flow
$134M
Beta
1.05
Next Earnings
Jun 5, 2025
Ex-Dividend
N/A
Next Dividend
N/A
KURA Overview
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine KURA's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
KURA
Ranked#26 of 462
Ranked#26 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.96 | A | |
| $8.12 | A | |
| $24.28 | A |
Be the first to know about important KURA news, forecast changes, insider trades & much more!
KURA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KURA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KURA ($6.52) is undervalued by 47.97% relative to our estimate of its Fair Value price of $12.53 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
KURA ($6.52) is significantly undervalued by 47.97% relative to our estimate of its Fair Value price of $12.53 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
KURA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KURA due diligence checks available for Premium users.
Valuation
KURA fair value
Fair Value of KURA stock based on Discounted Cash Flow (DCF)
Price
$6.52
Fair Value
$12.53
Undervalued by
47.97%
KURA ($6.52) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KURA ($6.52) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KURA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KURA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.23x
Industry
-158.75x
Market
29.19x
KURA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.27x
Industry
4.37x
KURA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KURA's financial health
Profit margin
Revenue
$53.9M
Net Income
-$19.2M
Profit Margin
-35.7%
KURA's Earnings (EBIT) of -$170.35M... subscribe to Premium to read more.
Interest Coverage Financials
KURA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$760.2M
Liabilities
$346.5M
Debt to equity
0.84
KURA's short-term assets ($744.83M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KURA's short-term assets ($744.83M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KURA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
KURA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$269.1M
Investing
-$95.0M
Financing
$806.0k
KURA's operating cash flow ($134.32M)... subscribe to Premium to read more.
Debt Coverage Financials
KURA vs Biotech Stocks
Kura Oncology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.